nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—hematologic cancer	0.108	0.512	CbGaD
Canagliflozin—ABCB1—hematologic cancer	0.103	0.488	CbGaD
Canagliflozin—ORM1—Imatinib—hematologic cancer	0.0361	0.0745	CbGbCtD
Canagliflozin—ABCC2—Daunorubicin—hematologic cancer	0.0318	0.0656	CbGbCtD
Canagliflozin—UGT1A9—Irinotecan—hematologic cancer	0.0306	0.0631	CbGbCtD
Canagliflozin—ABCB1—Lenalidomide—hematologic cancer	0.0177	0.0365	CbGbCtD
Canagliflozin—ABCC2—Irinotecan—hematologic cancer	0.0152	0.0314	CbGbCtD
Canagliflozin—ALB—Imatinib—hematologic cancer	0.0152	0.0313	CbGbCtD
Canagliflozin—ABCC2—Vinblastine—hematologic cancer	0.0135	0.0279	CbGbCtD
Canagliflozin—ABCC2—Vincristine—hematologic cancer	0.0133	0.0274	CbGbCtD
Canagliflozin—ABCC2—Cisplatin—hematologic cancer	0.0124	0.0256	CbGbCtD
Canagliflozin—ABCC2—Etoposide—hematologic cancer	0.0122	0.0252	CbGbCtD
Canagliflozin—CYP3A4—Bexarotene—hematologic cancer	0.0106	0.0219	CbGbCtD
Canagliflozin—ABCB1—Daunorubicin—hematologic cancer	0.0104	0.0214	CbGbCtD
Canagliflozin—ABCB1—Alitretinoin—hematologic cancer	0.0102	0.021	CbGbCtD
Canagliflozin—ABCC2—Dexamethasone—hematologic cancer	0.01	0.0207	CbGbCtD
Canagliflozin—ALB—Prednisone—hematologic cancer	0.01	0.0206	CbGbCtD
Canagliflozin—CYP3A4—Busulfan—hematologic cancer	0.00986	0.0203	CbGbCtD
Canagliflozin—CYP3A4—Lomustine—hematologic cancer	0.00986	0.0203	CbGbCtD
Canagliflozin—ALB—Irinotecan—hematologic cancer	0.0095	0.0196	CbGbCtD
Canagliflozin—CYP3A4—Thiotepa—hematologic cancer	0.00879	0.0181	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—hematologic cancer	0.00832	0.0172	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—hematologic cancer	0.00806	0.0166	CbGbCtD
Canagliflozin—ABCB1—Imatinib—hematologic cancer	0.00795	0.0164	CbGbCtD
Canagliflozin—ABCB1—Nilotinib—hematologic cancer	0.00723	0.0149	CbGbCtD
Canagliflozin—ABCB1—Vinorelbine—hematologic cancer	0.00717	0.0148	CbGbCtD
Canagliflozin—CYP3A4—Methoxsalen—hematologic cancer	0.00684	0.0141	CbGbCtD
Canagliflozin—CYP3A4—Bortezomib—hematologic cancer	0.0065	0.0134	CbGbCtD
Canagliflozin—ABCB1—Dasatinib—hematologic cancer	0.00639	0.0132	CbGbCtD
Canagliflozin—ABCB1—Mitoxantrone—hematologic cancer	0.00631	0.013	CbGbCtD
Canagliflozin—CYP3A4—Daunorubicin—hematologic cancer	0.00622	0.0128	CbGbCtD
Canagliflozin—ABCB1—Betamethasone—hematologic cancer	0.00562	0.0116	CbGbCtD
Canagliflozin—ABCB1—Gemcitabine—hematologic cancer	0.00557	0.0115	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—hematologic cancer	0.00555	0.0114	CbGbCtD
Canagliflozin—CYP3A4—Cytarabine—hematologic cancer	0.00549	0.0113	CbGbCtD
Canagliflozin—CYP3A4—Teniposide—hematologic cancer	0.0054	0.0111	CbGbCtD
Canagliflozin—ABCB1—Prednisone—hematologic cancer	0.00524	0.0108	CbGbCtD
Canagliflozin—ALB—Methotrexate—hematologic cancer	0.00503	0.0104	CbGbCtD
Canagliflozin—CYP3A4—Ifosfamide—hematologic cancer	0.00499	0.0103	CbGbCtD
Canagliflozin—ABCB1—Irinotecan—hematologic cancer	0.00497	0.0102	CbGbCtD
Canagliflozin—CYP3A4—Imatinib—hematologic cancer	0.00476	0.00982	CbGbCtD
Canagliflozin—CYP3A4—Ruxolitinib—hematologic cancer	0.00449	0.00925	CbGbCtD
Canagliflozin—ABCB1—Vinblastine—hematologic cancer	0.00442	0.0091	CbGbCtD
Canagliflozin—ABCB1—Vincristine—hematologic cancer	0.00434	0.00895	CbGbCtD
Canagliflozin—CYP3A4—Nilotinib—hematologic cancer	0.00433	0.00892	CbGbCtD
Canagliflozin—CYP3A4—Vinorelbine—hematologic cancer	0.00429	0.00885	CbGbCtD
Canagliflozin—ABCB1—Cisplatin—hematologic cancer	0.00405	0.00834	CbGbCtD
Canagliflozin—ABCB1—Etoposide—hematologic cancer	0.00398	0.0082	CbGbCtD
Canagliflozin—CYP3A4—Triamcinolone—hematologic cancer	0.00393	0.00809	CbGbCtD
Canagliflozin—CYP3A4—Dasatinib—hematologic cancer	0.00383	0.00789	CbGbCtD
Canagliflozin—CYP3A4—Mitoxantrone—hematologic cancer	0.00378	0.00779	CbGbCtD
Canagliflozin—CYP3A4—Betamethasone—hematologic cancer	0.00337	0.00694	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—hematologic cancer	0.00332	0.00685	CbGbCtD
Canagliflozin—ABCB1—Dexamethasone—hematologic cancer	0.00327	0.00674	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—hematologic cancer	0.00314	0.00647	CbGbCtD
Canagliflozin—SLC5A2—blood—hematologic cancer	0.00311	0.152	CbGeAlD
Canagliflozin—CYP3A4—Irinotecan—hematologic cancer	0.00298	0.00613	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—hematologic cancer	0.00271	0.00559	CbGbCtD
Canagliflozin—CYP3A4—Vinblastine—hematologic cancer	0.00265	0.00545	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—hematologic cancer	0.00263	0.00542	CbGbCtD
Canagliflozin—CYP3A4—Vincristine—hematologic cancer	0.0026	0.00536	CbGbCtD
Canagliflozin—SLC5A2—testis—hematologic cancer	0.00258	0.126	CbGeAlD
Canagliflozin—CYP3A4—Etoposide—hematologic cancer	0.00238	0.00491	CbGbCtD
Canagliflozin—SLC5A1—lung—hematologic cancer	0.00207	0.101	CbGeAlD
Canagliflozin—CYP3A4—Dexamethasone—hematologic cancer	0.00196	0.00404	CbGbCtD
Canagliflozin—SLC5A1—testis—hematologic cancer	0.00195	0.0955	CbGeAlD
Canagliflozin—UGT2B4—lung—hematologic cancer	0.00191	0.0933	CbGeAlD
Canagliflozin—CYP3A4—Doxorubicin—hematologic cancer	0.00163	0.00335	CbGbCtD
Canagliflozin—ORM1—hematopoietic system—hematologic cancer	0.00118	0.0577	CbGeAlD
Canagliflozin—ORM1—blood—hematologic cancer	0.000782	0.0382	CbGeAlD
Canagliflozin—ORM1—bone marrow—hematologic cancer	0.000756	0.037	CbGeAlD
Canagliflozin—ORM1—lung—hematologic cancer	0.000685	0.0335	CbGeAlD
Canagliflozin—ABCC2—blood—hematologic cancer	0.000642	0.0314	CbGeAlD
Canagliflozin—ALB—testis—hematologic cancer	0.000567	0.0277	CbGeAlD
Canagliflozin—ABCC2—testis—hematologic cancer	0.000531	0.026	CbGeAlD
Canagliflozin—CYP3A4—hematopoietic system—hematologic cancer	0.000492	0.0241	CbGeAlD
Canagliflozin—ORM1—lymph node—hematologic cancer	0.000469	0.0229	CbGeAlD
Canagliflozin—ALB—lymph node—hematologic cancer	0.000411	0.0201	CbGeAlD
Canagliflozin—ABCC2—lymph node—hematologic cancer	0.000385	0.0188	CbGeAlD
Canagliflozin—ABCB1—hematopoietic system—hematologic cancer	0.000349	0.0171	CbGeAlD
Canagliflozin—CYP3A4—blood—hematologic cancer	0.000326	0.016	CbGeAlD
Canagliflozin—ABCB1—gonad—hematologic cancer	0.000265	0.013	CbGeAlD
Canagliflozin—Dapagliflozin—ABCB1—hematologic cancer	0.000248	1	CrCbGaD
Canagliflozin—ABCB1—blood—hematologic cancer	0.000231	0.0113	CbGeAlD
Canagliflozin—ABCB1—bone marrow—hematologic cancer	0.000223	0.0109	CbGeAlD
Canagliflozin—ABCB1—lung—hematologic cancer	0.000202	0.0099	CbGeAlD
Canagliflozin—ABCB1—testis—hematologic cancer	0.000191	0.00935	CbGeAlD
Canagliflozin—ABCB1—lymph node—hematologic cancer	0.000138	0.00677	CbGeAlD
Canagliflozin—Breast disorder—Doxorubicin—hematologic cancer	5.24e-05	0.000274	CcSEcCtD
Canagliflozin—Hypersensitivity—Carmustine—hematologic cancer	5.24e-05	0.000274	CcSEcCtD
Canagliflozin—Pruritus—Thalidomide—hematologic cancer	5.24e-05	0.000274	CcSEcCtD
Canagliflozin—Abdominal pain—Irinotecan—hematologic cancer	5.23e-05	0.000273	CcSEcCtD
Canagliflozin—Abdominal pain—Mitoxantrone—hematologic cancer	5.23e-05	0.000273	CcSEcCtD
Canagliflozin—Nausea—Hydroxyurea—hematologic cancer	5.23e-05	0.000273	CcSEcCtD
Canagliflozin—Hypersensitivity—Alitretinoin—hematologic cancer	5.19e-05	0.000271	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cisplatin—hematologic cancer	5.18e-05	0.000271	CcSEcCtD
Canagliflozin—Rash—Bortezomib—hematologic cancer	5.18e-05	0.000271	CcSEcCtD
Canagliflozin—Dermatitis—Bortezomib—hematologic cancer	5.17e-05	0.00027	CcSEcCtD
Canagliflozin—Hypotension—Etoposide—hematologic cancer	5.14e-05	0.000269	CcSEcCtD
Canagliflozin—Rash—Bleomycin—hematologic cancer	5.14e-05	0.000269	CcSEcCtD
Canagliflozin—Dermatitis—Bleomycin—hematologic cancer	5.13e-05	0.000268	CcSEcCtD
Canagliflozin—Hypersensitivity—Ifosfamide—hematologic cancer	5.13e-05	0.000268	CcSEcCtD
Canagliflozin—Asthenia—Carmustine—hematologic cancer	5.1e-05	0.000267	CcSEcCtD
Canagliflozin—Dry mouth—Triamcinolone—hematologic cancer	5.09e-05	0.000266	CcSEcCtD
Canagliflozin—Angioedema—Dexamethasone—hematologic cancer	5.07e-05	0.000265	CcSEcCtD
Canagliflozin—Angioedema—Betamethasone—hematologic cancer	5.07e-05	0.000265	CcSEcCtD
Canagliflozin—Dizziness—Thiotepa—hematologic cancer	5.06e-05	0.000265	CcSEcCtD
Canagliflozin—Asthenia—Alitretinoin—hematologic cancer	5.05e-05	0.000264	CcSEcCtD
Canagliflozin—Rash—Vinorelbine—hematologic cancer	5.05e-05	0.000264	CcSEcCtD
Canagliflozin—Dermatitis—Vinorelbine—hematologic cancer	5.05e-05	0.000264	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—hematologic cancer	5.03e-05	0.000263	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—hematologic cancer	5.01e-05	0.000262	CcSEcCtD
Canagliflozin—Hypersensitivity—Vincristine—hematologic cancer	5e-05	0.000262	CcSEcCtD
Canagliflozin—Asthenia—Ifosfamide—hematologic cancer	5e-05	0.000261	CcSEcCtD
Canagliflozin—Pruritus—Alitretinoin—hematologic cancer	4.98e-05	0.000261	CcSEcCtD
Canagliflozin—Syncope—Dexamethasone—hematologic cancer	4.97e-05	0.00026	CcSEcCtD
Canagliflozin—Syncope—Betamethasone—hematologic cancer	4.97e-05	0.00026	CcSEcCtD
Canagliflozin—Infection—Triamcinolone—hematologic cancer	4.96e-05	0.000259	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—hematologic cancer	4.95e-05	0.000259	CcSEcCtD
Canagliflozin—Pruritus—Ifosfamide—hematologic cancer	4.93e-05	0.000258	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—hematologic cancer	4.92e-05	0.000257	CcSEcCtD
Canagliflozin—Shock—Triamcinolone—hematologic cancer	4.91e-05	0.000257	CcSEcCtD
Canagliflozin—Dizziness—Thalidomide—hematologic cancer	4.9e-05	0.000256	CcSEcCtD
Canagliflozin—Nausea—Bortezomib—hematologic cancer	4.88e-05	0.000255	CcSEcCtD
Canagliflozin—Loss of consciousness—Betamethasone—hematologic cancer	4.87e-05	0.000255	CcSEcCtD
Canagliflozin—Loss of consciousness—Dexamethasone—hematologic cancer	4.87e-05	0.000255	CcSEcCtD
Canagliflozin—Hypersensitivity—Mitoxantrone—hematologic cancer	4.87e-05	0.000255	CcSEcCtD
Canagliflozin—Hypersensitivity—Irinotecan—hematologic cancer	4.87e-05	0.000255	CcSEcCtD
Canagliflozin—Asthenia—Vincristine—hematologic cancer	4.87e-05	0.000255	CcSEcCtD
Canagliflozin—Nausea—Bleomycin—hematologic cancer	4.84e-05	0.000253	CcSEcCtD
Canagliflozin—Erythema—Prednisone—hematologic cancer	4.83e-05	0.000253	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—hematologic cancer	4.83e-05	0.000253	CcSEcCtD
Canagliflozin—Rash—Thiotepa—hematologic cancer	4.83e-05	0.000252	CcSEcCtD
Canagliflozin—Dermatitis—Thiotepa—hematologic cancer	4.82e-05	0.000252	CcSEcCtD
Canagliflozin—Convulsion—Betamethasone—hematologic cancer	4.8e-05	0.000251	CcSEcCtD
Canagliflozin—Convulsion—Dexamethasone—hematologic cancer	4.8e-05	0.000251	CcSEcCtD
Canagliflozin—Nausea—Vinorelbine—hematologic cancer	4.76e-05	0.000249	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—hematologic cancer	4.75e-05	0.000248	CcSEcCtD
Canagliflozin—Asthenia—Irinotecan—hematologic cancer	4.74e-05	0.000248	CcSEcCtD
Canagliflozin—Asthenia—Mitoxantrone—hematologic cancer	4.74e-05	0.000248	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—hematologic cancer	4.74e-05	0.000248	CcSEcCtD
Canagliflozin—Dizziness—Carmustine—hematologic cancer	4.7e-05	0.000246	CcSEcCtD
Canagliflozin—Constipation—Etoposide—hematologic cancer	4.7e-05	0.000246	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—hematologic cancer	4.7e-05	0.000246	CcSEcCtD
Canagliflozin—Rash—Thalidomide—hematologic cancer	4.67e-05	0.000244	CcSEcCtD
Canagliflozin—Dermatitis—Thalidomide—hematologic cancer	4.66e-05	0.000244	CcSEcCtD
Canagliflozin—Dizziness—Alitretinoin—hematologic cancer	4.66e-05	0.000244	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—hematologic cancer	4.63e-05	0.000242	CcSEcCtD
Canagliflozin—Asthenia—Gemcitabine—hematologic cancer	4.62e-05	0.000242	CcSEcCtD
Canagliflozin—Dizziness—Ifosfamide—hematologic cancer	4.6e-05	0.000241	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—hematologic cancer	4.58e-05	0.000239	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—hematologic cancer	4.58e-05	0.000239	CcSEcCtD
Canagliflozin—Pruritus—Gemcitabine—hematologic cancer	4.56e-05	0.000238	CcSEcCtD
Canagliflozin—Nausea—Thiotepa—hematologic cancer	4.55e-05	0.000238	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—hematologic cancer	4.54e-05	0.000238	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—hematologic cancer	4.5e-05	0.000235	CcSEcCtD
Canagliflozin—Infection—Betamethasone—hematologic cancer	4.5e-05	0.000235	CcSEcCtD
Canagliflozin—Infection—Dexamethasone—hematologic cancer	4.5e-05	0.000235	CcSEcCtD
Canagliflozin—Dizziness—Vincristine—hematologic cancer	4.49e-05	0.000235	CcSEcCtD
Canagliflozin—Rash—Carmustine—hematologic cancer	4.48e-05	0.000235	CcSEcCtD
Canagliflozin—Dermatitis—Carmustine—hematologic cancer	4.48e-05	0.000234	CcSEcCtD
Canagliflozin—Shock—Betamethasone—hematologic cancer	4.45e-05	0.000233	CcSEcCtD
Canagliflozin—Shock—Dexamethasone—hematologic cancer	4.45e-05	0.000233	CcSEcCtD
Canagliflozin—Rash—Alitretinoin—hematologic cancer	4.44e-05	0.000232	CcSEcCtD
Canagliflozin—Nervous system disorder—Betamethasone—hematologic cancer	4.44e-05	0.000232	CcSEcCtD
Canagliflozin—Nervous system disorder—Dexamethasone—hematologic cancer	4.44e-05	0.000232	CcSEcCtD
Canagliflozin—Dermatitis—Alitretinoin—hematologic cancer	4.44e-05	0.000232	CcSEcCtD
Canagliflozin—Hypersensitivity—Cisplatin—hematologic cancer	4.42e-05	0.000231	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—hematologic cancer	4.41e-05	0.000231	CcSEcCtD
Canagliflozin—Nausea—Thalidomide—hematologic cancer	4.4e-05	0.00023	CcSEcCtD
Canagliflozin—Rash—Ifosfamide—hematologic cancer	4.39e-05	0.00023	CcSEcCtD
Canagliflozin—Dermatitis—Ifosfamide—hematologic cancer	4.39e-05	0.000229	CcSEcCtD
Canagliflozin—Dizziness—Irinotecan—hematologic cancer	4.37e-05	0.000229	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—hematologic cancer	4.37e-05	0.000228	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—hematologic cancer	4.35e-05	0.000227	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—hematologic cancer	4.35e-05	0.000227	CcSEcCtD
Canagliflozin—Syncope—Prednisone—hematologic cancer	4.33e-05	0.000227	CcSEcCtD
Canagliflozin—Urticaria—Prednisolone—hematologic cancer	4.31e-05	0.000225	CcSEcCtD
Canagliflozin—Asthenia—Cisplatin—hematologic cancer	4.31e-05	0.000225	CcSEcCtD
Canagliflozin—Fatigue—Triamcinolone—hematologic cancer	4.3e-05	0.000225	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—hematologic cancer	4.28e-05	0.000224	CcSEcCtD
Canagliflozin—Rash—Vincristine—hematologic cancer	4.28e-05	0.000224	CcSEcCtD
Canagliflozin—Dermatitis—Vincristine—hematologic cancer	4.28e-05	0.000224	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—hematologic cancer	4.25e-05	0.000222	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisone—hematologic cancer	4.24e-05	0.000222	CcSEcCtD
Canagliflozin—Hypotension—Dexamethasone—hematologic cancer	4.23e-05	0.000221	CcSEcCtD
Canagliflozin—Hypotension—Betamethasone—hematologic cancer	4.23e-05	0.000221	CcSEcCtD
Canagliflozin—Nausea—Carmustine—hematologic cancer	4.22e-05	0.000221	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—hematologic cancer	4.21e-05	0.00022	CcSEcCtD
Canagliflozin—Nausea—Alitretinoin—hematologic cancer	4.18e-05	0.000219	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—hematologic cancer	4.18e-05	0.000219	CcSEcCtD
Canagliflozin—Rash—Mitoxantrone—hematologic cancer	4.17e-05	0.000218	CcSEcCtD
Canagliflozin—Rash—Irinotecan—hematologic cancer	4.17e-05	0.000218	CcSEcCtD
Canagliflozin—Dermatitis—Mitoxantrone—hematologic cancer	4.16e-05	0.000218	CcSEcCtD
Canagliflozin—Dermatitis—Irinotecan—hematologic cancer	4.16e-05	0.000218	CcSEcCtD
Canagliflozin—Nausea—Ifosfamide—hematologic cancer	4.14e-05	0.000216	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.08e-05	0.000214	CcSEcCtD
Canagliflozin—Rash—Gemcitabine—hematologic cancer	4.06e-05	0.000212	CcSEcCtD
Canagliflozin—Dermatitis—Gemcitabine—hematologic cancer	4.06e-05	0.000212	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—hematologic cancer	4.05e-05	0.000212	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—hematologic cancer	4.04e-05	0.000211	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—hematologic cancer	4.04e-05	0.000211	CcSEcCtD
Canagliflozin—Nausea—Vincristine—hematologic cancer	4.03e-05	0.000211	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisolone—hematologic cancer	4e-05	0.000209	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—hematologic cancer	3.96e-05	0.000207	CcSEcCtD
Canagliflozin—Urticaria—Triamcinolone—hematologic cancer	3.96e-05	0.000207	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—hematologic cancer	3.95e-05	0.000206	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—hematologic cancer	3.94e-05	0.000206	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—hematologic cancer	3.94e-05	0.000206	CcSEcCtD
Canagliflozin—Nausea—Mitoxantrone—hematologic cancer	3.93e-05	0.000205	CcSEcCtD
Canagliflozin—Nausea—Irinotecan—hematologic cancer	3.93e-05	0.000205	CcSEcCtD
Canagliflozin—Infection—Prednisone—hematologic cancer	3.92e-05	0.000205	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.91e-05	0.000204	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.91e-05	0.000204	CcSEcCtD
Canagliflozin—Fatigue—Betamethasone—hematologic cancer	3.9e-05	0.000204	CcSEcCtD
Canagliflozin—Fatigue—Dexamethasone—hematologic cancer	3.9e-05	0.000204	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—hematologic cancer	3.89e-05	0.000203	CcSEcCtD
Canagliflozin—Shock—Prednisone—hematologic cancer	3.88e-05	0.000203	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—hematologic cancer	3.87e-05	0.000202	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—hematologic cancer	3.83e-05	0.0002	CcSEcCtD
Canagliflozin—Nausea—Gemcitabine—hematologic cancer	3.83e-05	0.0002	CcSEcCtD
Canagliflozin—Rash—Cisplatin—hematologic cancer	3.78e-05	0.000198	CcSEcCtD
Canagliflozin—Dermatitis—Cisplatin—hematologic cancer	3.78e-05	0.000198	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—hematologic cancer	3.78e-05	0.000198	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—hematologic cancer	3.78e-05	0.000198	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.7e-05	0.000194	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Betamethasone—hematologic cancer	3.7e-05	0.000194	CcSEcCtD
Canagliflozin—Hypersensitivity—Triamcinolone—hematologic cancer	3.67e-05	0.000192	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—hematologic cancer	3.64e-05	0.00019	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—hematologic cancer	3.64e-05	0.00019	CcSEcCtD
Canagliflozin—Urticaria—Betamethasone—hematologic cancer	3.6e-05	0.000188	CcSEcCtD
Canagliflozin—Urticaria—Dexamethasone—hematologic cancer	3.6e-05	0.000188	CcSEcCtD
Canagliflozin—Dizziness—Prednisolone—hematologic cancer	3.59e-05	0.000188	CcSEcCtD
Canagliflozin—Asthenia—Triamcinolone—hematologic cancer	3.58e-05	0.000187	CcSEcCtD
Canagliflozin—Abdominal pain—Betamethasone—hematologic cancer	3.58e-05	0.000187	CcSEcCtD
Canagliflozin—Abdominal pain—Dexamethasone—hematologic cancer	3.58e-05	0.000187	CcSEcCtD
Canagliflozin—Nausea—Cisplatin—hematologic cancer	3.57e-05	0.000186	CcSEcCtD
Canagliflozin—Pruritus—Triamcinolone—hematologic cancer	3.53e-05	0.000185	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—hematologic cancer	3.5e-05	0.000183	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—hematologic cancer	3.49e-05	0.000183	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—hematologic cancer	3.49e-05	0.000183	CcSEcCtD
Canagliflozin—Rash—Etoposide—hematologic cancer	3.47e-05	0.000181	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—hematologic cancer	3.46e-05	0.000181	CcSEcCtD
Canagliflozin—Rash—Prednisolone—hematologic cancer	3.42e-05	0.000179	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—hematologic cancer	3.42e-05	0.000179	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.41e-05	0.000178	CcSEcCtD
Canagliflozin—Fatigue—Prednisone—hematologic cancer	3.4e-05	0.000178	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—hematologic cancer	3.39e-05	0.000177	CcSEcCtD
Canagliflozin—Constipation—Prednisone—hematologic cancer	3.37e-05	0.000176	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—hematologic cancer	3.32e-05	0.000174	CcSEcCtD
Canagliflozin—Dizziness—Triamcinolone—hematologic cancer	3.3e-05	0.000173	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—hematologic cancer	3.27e-05	0.000171	CcSEcCtD
Canagliflozin—Infection—Methotrexate—hematologic cancer	3.27e-05	0.000171	CcSEcCtD
Canagliflozin—Nausea—Etoposide—hematologic cancer	3.27e-05	0.000171	CcSEcCtD
Canagliflozin—Asthenia—Betamethasone—hematologic cancer	3.25e-05	0.00017	CcSEcCtD
Canagliflozin—Asthenia—Dexamethasone—hematologic cancer	3.25e-05	0.00017	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—hematologic cancer	3.23e-05	0.000169	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Prednisone—hematologic cancer	3.22e-05	0.000169	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—hematologic cancer	3.22e-05	0.000168	CcSEcCtD
Canagliflozin—Pruritus—Dexamethasone—hematologic cancer	3.2e-05	0.000167	CcSEcCtD
Canagliflozin—Pruritus—Betamethasone—hematologic cancer	3.2e-05	0.000167	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—hematologic cancer	3.2e-05	0.000167	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.19e-05	0.000167	CcSEcCtD
Canagliflozin—Rash—Triamcinolone—hematologic cancer	3.14e-05	0.000164	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—hematologic cancer	3.14e-05	0.000164	CcSEcCtD
Canagliflozin—Dermatitis—Triamcinolone—hematologic cancer	3.14e-05	0.000164	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—hematologic cancer	3.13e-05	0.000164	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—hematologic cancer	3.13e-05	0.000164	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—hematologic cancer	3.12e-05	0.000163	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—hematologic cancer	3.08e-05	0.000161	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—hematologic cancer	3.07e-05	0.000161	CcSEcCtD
Canagliflozin—Infection—Epirubicin—hematologic cancer	3.06e-05	0.00016	CcSEcCtD
Canagliflozin—Shock—Epirubicin—hematologic cancer	3.03e-05	0.000159	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—hematologic cancer	3.03e-05	0.000158	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—hematologic cancer	3.02e-05	0.000158	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—hematologic cancer	2.99e-05	0.000157	CcSEcCtD
Canagliflozin—Dizziness—Dexamethasone—hematologic cancer	2.99e-05	0.000157	CcSEcCtD
Canagliflozin—Dizziness—Betamethasone—hematologic cancer	2.99e-05	0.000157	CcSEcCtD
Canagliflozin—Nausea—Triamcinolone—hematologic cancer	2.96e-05	0.000155	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.95e-05	0.000155	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—hematologic cancer	2.91e-05	0.000152	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—hematologic cancer	2.9e-05	0.000152	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—hematologic cancer	2.88e-05	0.000151	CcSEcCtD
Canagliflozin—Rash—Betamethasone—hematologic cancer	2.85e-05	0.000149	CcSEcCtD
Canagliflozin—Rash—Dexamethasone—hematologic cancer	2.85e-05	0.000149	CcSEcCtD
Canagliflozin—Dermatitis—Dexamethasone—hematologic cancer	2.85e-05	0.000149	CcSEcCtD
Canagliflozin—Dermatitis—Betamethasone—hematologic cancer	2.85e-05	0.000149	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.84e-05	0.000149	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—hematologic cancer	2.84e-05	0.000149	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—hematologic cancer	2.83e-05	0.000148	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—hematologic cancer	2.83e-05	0.000148	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—hematologic cancer	2.81e-05	0.000147	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—hematologic cancer	2.8e-05	0.000146	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—hematologic cancer	2.79e-05	0.000146	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—hematologic cancer	2.77e-05	0.000145	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—hematologic cancer	2.69e-05	0.000141	CcSEcCtD
Canagliflozin—Nausea—Betamethasone—hematologic cancer	2.69e-05	0.000141	CcSEcCtD
Canagliflozin—Nausea—Dexamethasone—hematologic cancer	2.69e-05	0.000141	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—hematologic cancer	2.67e-05	0.000139	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.66e-05	0.000139	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—hematologic cancer	2.66e-05	0.000139	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—hematologic cancer	2.64e-05	0.000138	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—hematologic cancer	2.62e-05	0.000137	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—hematologic cancer	2.61e-05	0.000136	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—hematologic cancer	2.6e-05	0.000136	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—hematologic cancer	2.52e-05	0.000132	CcSEcCtD
Canagliflozin—Rash—Prednisone—hematologic cancer	2.49e-05	0.00013	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—hematologic cancer	2.48e-05	0.00013	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.46e-05	0.000129	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—hematologic cancer	2.46e-05	0.000129	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—hematologic cancer	2.45e-05	0.000128	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—hematologic cancer	2.44e-05	0.000128	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—hematologic cancer	2.44e-05	0.000127	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—hematologic cancer	2.43e-05	0.000127	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—hematologic cancer	2.36e-05	0.000124	CcSEcCtD
Canagliflozin—Nausea—Prednisone—hematologic cancer	2.34e-05	0.000122	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.33e-05	0.000122	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—hematologic cancer	2.33e-05	0.000122	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—hematologic cancer	2.27e-05	0.000119	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—hematologic cancer	2.27e-05	0.000119	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—hematologic cancer	2.25e-05	0.000118	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—hematologic cancer	2.21e-05	0.000116	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—hematologic cancer	2.18e-05	0.000114	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—hematologic cancer	2.18e-05	0.000114	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—hematologic cancer	2.1e-05	0.00011	CcSEcCtD
Canagliflozin—Rash—Methotrexate—hematologic cancer	2.08e-05	0.000109	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—hematologic cancer	2.07e-05	0.000109	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—hematologic cancer	2.05e-05	0.000107	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—hematologic cancer	2.04e-05	0.000107	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—hematologic cancer	2.02e-05	0.000106	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—hematologic cancer	1.96e-05	0.000102	CcSEcCtD
Canagliflozin—Rash—Epirubicin—hematologic cancer	1.94e-05	0.000102	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—hematologic cancer	1.94e-05	0.000102	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—hematologic cancer	1.89e-05	9.86e-05	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—hematologic cancer	1.83e-05	9.58e-05	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—hematologic cancer	1.8e-05	9.41e-05	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—hematologic cancer	1.8e-05	9.4e-05	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—hematologic cancer	1.69e-05	8.86e-05	CcSEcCtD
Canagliflozin—ALB—Hemostasis—ABL1—hematologic cancer	9.69e-06	0.000105	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—hematologic cancer	9.47e-06	0.000103	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FHL2—hematologic cancer	9.46e-06	0.000102	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—hematologic cancer	9.46e-06	0.000102	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—hematologic cancer	9.46e-06	0.000102	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—hematologic cancer	9.37e-06	0.000102	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTAP—hematologic cancer	9.3e-06	0.000101	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	9.29e-06	0.000101	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AGRN—hematologic cancer	9.28e-06	0.0001	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—hematologic cancer	9.23e-06	0.0001	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NQO1—hematologic cancer	9.2e-06	9.97e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD44—hematologic cancer	9.2e-06	9.97e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HGF—hematologic cancer	9.11e-06	9.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	9.11e-06	9.86e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—hematologic cancer	9.05e-06	9.81e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—hematologic cancer	9.05e-06	9.81e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	9.01e-06	9.76e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CSF2—hematologic cancer	9.01e-06	9.76e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—EP300—hematologic cancer	8.94e-06	9.68e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SMPD3—hematologic cancer	8.89e-06	9.63e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	8.86e-06	9.6e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	8.85e-06	9.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMMR—hematologic cancer	8.79e-06	9.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—IDH2—hematologic cancer	8.79e-06	9.53e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYCS—hematologic cancer	8.71e-06	9.43e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKCG—hematologic cancer	8.69e-06	9.42e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—JAK1—hematologic cancer	8.69e-06	9.42e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HSP90AA1—hematologic cancer	8.65e-06	9.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	8.57e-06	9.29e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—hematologic cancer	8.56e-06	9.28e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—hematologic cancer	8.56e-06	9.28e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	8.56e-06	9.27e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	8.53e-06	9.24e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	8.37e-06	9.07e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—hematologic cancer	8.35e-06	9.05e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—hematologic cancer	8.35e-06	9.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	8.29e-06	8.98e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FHL2—hematologic cancer	8.29e-06	8.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ARNTL—hematologic cancer	8.27e-06	8.96e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	8.16e-06	8.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AGRN—hematologic cancer	8.13e-06	8.81e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—hematologic cancer	8.12e-06	8.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2RA—hematologic cancer	8.12e-06	8.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SRC—hematologic cancer	8.06e-06	8.73e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ACP5—hematologic cancer	8.04e-06	8.71e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA9—hematologic cancer	8.04e-06	8.71e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOR2—hematologic cancer	7.94e-06	8.6e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	7.93e-06	8.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	7.85e-06	8.5e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PDGFB—hematologic cancer	7.84e-06	8.49e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.79e-06	8.44e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—DCK—hematologic cancer	7.77e-06	8.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ASNS—hematologic cancer	7.77e-06	8.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—B3GAT1—hematologic cancer	7.77e-06	8.42e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	7.73e-06	8.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—IDH2—hematologic cancer	7.71e-06	8.35e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMMR—hematologic cancer	7.71e-06	8.35e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—hematologic cancer	7.68e-06	8.32e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CDK2—hematologic cancer	7.6e-06	8.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—IDH1—hematologic cancer	7.56e-06	8.19e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TXN—hematologic cancer	7.48e-06	8.1e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTO1—hematologic cancer	7.48e-06	8.1e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCC3—hematologic cancer	7.48e-06	8.1e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.43e-06	8.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	7.42e-06	8.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HDC—hematologic cancer	7.37e-06	7.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SPHK1—hematologic cancer	7.32e-06	7.93e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	7.31e-06	7.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK14—hematologic cancer	7.29e-06	7.9e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—hematologic cancer	7.27e-06	7.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ARNTL—hematologic cancer	7.25e-06	7.85e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	7.2e-06	7.8e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	7.11e-06	7.7e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	7.09e-06	7.68e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FN1—hematologic cancer	7.07e-06	7.66e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—hematologic cancer	7.05e-06	7.64e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NCOR1—hematologic cancer	7.05e-06	7.64e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ACP5—hematologic cancer	7.05e-06	7.63e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA9—hematologic cancer	7.05e-06	7.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—UGT1A1—hematologic cancer	7.03e-06	7.62e-05	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—hematologic cancer	6.99e-06	7.58e-05	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—hematologic cancer	6.99e-06	7.58e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOR2—hematologic cancer	6.96e-06	7.54e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC22A1—hematologic cancer	6.84e-06	7.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CRABP1—hematologic cancer	6.84e-06	7.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—hematologic cancer	6.76e-06	7.33e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CDA—hematologic cancer	6.74e-06	7.3e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALOX5—hematologic cancer	6.67e-06	7.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PTPN11—hematologic cancer	6.65e-06	7.2e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—IDH1—hematologic cancer	6.63e-06	7.18e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	6.62e-06	7.17e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—hematologic cancer	6.61e-06	7.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	6.57e-06	7.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCC3—hematologic cancer	6.55e-06	7.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTO1—hematologic cancer	6.55e-06	7.1e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TXN—hematologic cancer	6.55e-06	7.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PC—hematologic cancer	6.49e-06	7.03e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NUP98—hematologic cancer	6.46e-06	6.99e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SPHK1—hematologic cancer	6.41e-06	6.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CREBBP—hematologic cancer	6.27e-06	6.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADCY7—hematologic cancer	6.27e-06	6.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOA3—hematologic cancer	6.27e-06	6.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GBA—hematologic cancer	6.26e-06	6.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC35B2—hematologic cancer	6.26e-06	6.79e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—hematologic cancer	6.23e-06	6.75e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NUP214—hematologic cancer	6.22e-06	6.74e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—UGT1A1—hematologic cancer	6.16e-06	6.67e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.16e-06	6.67e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	6.13e-06	6.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTR—hematologic cancer	6.1e-06	6.6e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCG2—hematologic cancer	6.1e-06	6.6e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	6.04e-06	6.54e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC22A1—hematologic cancer	5.99e-06	6.49e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CRABP1—hematologic cancer	5.99e-06	6.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO2—hematologic cancer	5.98e-06	6.48e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—hematologic cancer	5.95e-06	6.44e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALOX5—hematologic cancer	5.84e-06	6.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	5.84e-06	6.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—hematologic cancer	5.8e-06	6.28e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTAP—hematologic cancer	5.73e-06	6.21e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	5.71e-06	6.18e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SDC1—hematologic cancer	5.67e-06	6.14e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NUP98—hematologic cancer	5.66e-06	6.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3R1—hematologic cancer	5.62e-06	6.08e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.49e-06	5.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADCY7—hematologic cancer	5.49e-06	5.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOA3—hematologic cancer	5.49e-06	5.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—JAK2—hematologic cancer	5.46e-06	5.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NUP214—hematologic cancer	5.45e-06	5.91e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.43e-06	5.88e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.41e-06	5.86e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—hematologic cancer	5.4e-06	5.85e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTR—hematologic cancer	5.34e-06	5.79e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ABCG2—hematologic cancer	5.34e-06	5.79e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—hematologic cancer	5.24e-06	5.67e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO2—hematologic cancer	5.24e-06	5.67e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—hematologic cancer	5.18e-06	5.61e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.11e-06	5.54e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FHL2—hematologic cancer	5.11e-06	5.53e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—hematologic cancer	5.08e-06	5.5e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AGRN—hematologic cancer	5.01e-06	5.43e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	5.01e-06	5.42e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SDC1—hematologic cancer	4.97e-06	5.38e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	4.93e-06	5.34e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CREBBP—hematologic cancer	4.86e-06	5.26e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NQO1—hematologic cancer	4.82e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD44—hematologic cancer	4.82e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—hematologic cancer	4.76e-06	5.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	4.76e-06	5.15e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMMR—hematologic cancer	4.75e-06	5.14e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—IDH2—hematologic cancer	4.75e-06	5.14e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.72e-06	5.11e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—hematologic cancer	4.6e-06	4.99e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYCS—hematologic cancer	4.56e-06	4.94e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—hematologic cancer	4.55e-06	4.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HSP90AA1—hematologic cancer	4.53e-06	4.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ARNTL—hematologic cancer	4.46e-06	4.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	4.45e-06	4.82e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3R1—hematologic cancer	4.35e-06	4.71e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACP5—hematologic cancer	4.34e-06	4.7e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA9—hematologic cancer	4.34e-06	4.7e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOR2—hematologic cancer	4.29e-06	4.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EP300—hematologic cancer	4.27e-06	4.63e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NQO1—hematologic cancer	4.22e-06	4.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD44—hematologic cancer	4.22e-06	4.57e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SRC—hematologic cancer	4.15e-06	4.5e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—IDH1—hematologic cancer	4.08e-06	4.42e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.08e-06	4.42e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—hematologic cancer	4.05e-06	4.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TXN—hematologic cancer	4.04e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.04e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.04e-06	4.37e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—hematologic cancer	4.02e-06	4.35e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—hematologic cancer	4.01e-06	4.35e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—hematologic cancer	4e-06	4.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYCS—hematologic cancer	4e-06	4.33e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.97e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.95e-06	4.28e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.89e-06	4.21e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—hematologic cancer	3.83e-06	4.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—hematologic cancer	3.8e-06	4.12e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.8e-06	4.11e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—hematologic cancer	3.71e-06	4.02e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NCOR1—hematologic cancer	3.69e-06	4e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—hematologic cancer	3.69e-06	4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.69e-06	4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.69e-06	4e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.6e-06	3.9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—hematologic cancer	3.52e-06	3.81e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NUP98—hematologic cancer	3.48e-06	3.77e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—hematologic cancer	3.47e-06	3.76e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—hematologic cancer	3.44e-06	3.73e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.38e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.38e-06	3.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NUP214—hematologic cancer	3.36e-06	3.64e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—EP300—hematologic cancer	3.31e-06	3.58e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.29e-06	3.56e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTR—hematologic cancer	3.29e-06	3.56e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—hematologic cancer	3.26e-06	3.54e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NCOR1—hematologic cancer	3.24e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—hematologic cancer	3.24e-06	3.51e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO2—hematologic cancer	3.23e-06	3.5e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—hematologic cancer	3.16e-06	3.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.13e-06	3.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SDC1—hematologic cancer	3.06e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—hematologic cancer	3.06e-06	3.31e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—hematologic cancer	2.92e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.88e-06	3.12e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—hematologic cancer	2.86e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—hematologic cancer	2.74e-06	2.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NQO1—hematologic cancer	2.6e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD44—hematologic cancer	2.6e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—hematologic cancer	2.58e-06	2.8e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CREBBP—hematologic cancer	2.54e-06	2.75e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYCS—hematologic cancer	2.46e-06	2.67e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—hematologic cancer	2.45e-06	2.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.45e-06	2.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—hematologic cancer	2.41e-06	2.61e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.4e-06	2.6e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3R1—hematologic cancer	2.28e-06	2.47e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CREBBP—hematologic cancer	2.23e-06	2.41e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.17e-06	2.35e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.11e-06	2.29e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—hematologic cancer	2.1e-06	2.28e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—hematologic cancer	2.09e-06	2.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.05e-06	2.22e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—hematologic cancer	2e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.99e-06	2.16e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.99e-06	2.16e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.99e-06	2.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.84e-06	1.99e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—hematologic cancer	1.82e-06	1.97e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.76e-06	1.91e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EP300—hematologic cancer	1.73e-06	1.88e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—hematologic cancer	1.59e-06	1.72e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EP300—hematologic cancer	1.52e-06	1.64e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.48e-06	1.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.37e-06	1.49e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.3e-06	1.41e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—hematologic cancer	1.28e-06	1.39e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—hematologic cancer	1.28e-06	1.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.23e-06	1.33e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.13e-06	1.23e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.12e-06	1.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—hematologic cancer	1.05e-06	1.13e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—hematologic cancer	9.8e-07	1.06e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EP300—hematologic cancer	9.35e-07	1.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—hematologic cancer	9.17e-07	9.93e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.92e-07	7.49e-06	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—hematologic cancer	5.65e-07	6.12e-06	CbGpPWpGaD
